Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 2,531 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Baseline Control Clear all

Conditions: Alcohol Risk Behaviors
Interventions: Intermittent Theta Burst Stimulation, Continuous Theta Burst Stimulation, Sham Transcranial Magnetic Stimulation; Device
Lead sponsor: Michael J. Wesley, PhD; Other
Eligibility: 21 Years to 29 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Chemotherapy-related Cognitive Impairment
Interventions: Low-Intensity Walking Intervention, Control Group Intervention; Behavioral
Lead sponsor: Ellis Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Schenectady, New York

Conditions: Diabetic Macular Edema
Interventions: Luminate 1.0mg, Luminate 2.0mg, Luminate 3.0mg, Avastin, Luminate 0.5mg; Drug
Lead sponsor: Allegro Ophthalmics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 17
States / cities: Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 14 more

Conditions: Implementation Science, Engagement, Patient, E Cigarette Use, Peer Support, Vaping Teens, Vaping Cessation, Parent Support
Interventions: Parents Helping Parents program; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 15 Years to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Gingivitis, DMFT Index, Dental Plaque Index, Oral Hygiene Education Methods, Oral Hygiene Reinforcement During Fixed Orthodontic Treatment, Motivational Interview, OHI
Interventions: Motivational Interviewing-Based Counseling, Standard Oral Health Education; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 19 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Age Related Maculopathy, Retinal Degeneration
Interventions: Module 1: Visual Awareness and Eccentric Viewing, Module 2: Control of Reading Eye Movements, Module 3: Reading Practice with RSVP; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma
Interventions: Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Asthma
Interventions: Iggy and the Inhalers Asthma Education for Kids; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 8 Years to 12 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: Obesity, Hypertension
Interventions: Lifestyle Modification Program, Usual Care and Reading Materials; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 365 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Arthritis, Psoriatic
Interventions: Secukinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 19
States / cities: Mesa, Arizona • Upland, California • Denver, Colorado + 15 more

Conditions: Self Efficacy, HIV Prevention, STI Prevention
Interventions: Treat Act Know Engage (T.A.K.E.) Steps, Standard or Care; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 13 Years to 19 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Philadelphia, Pennsylvania

Conditions: Overweight, Obesity, Sedentary Lifestyle
Interventions: Expert system-based physical activity counseling; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Constipation - Functional
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 87
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 78 more

Conditions: Volume Loss (Soft Tissue Ptosis or Atrophy )
Interventions: Hyperdiluted Calcium Hydroxylapatite, Calcium hydroxylapatite, Calcium hydroxylapatite with integral lidocaine; Device
Lead sponsor: Kalpna Kay Durairaj, MD, FACS; Other
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Hyperglycemia
Interventions: Brain MRS during hyperglycemic clamp, Analysis of Metabolites in cerebrospinal fluid; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Epilepsy
Interventions: Acoustic 1Hz Stimulation, Sham Background Noise; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: TBI (Traumatic Brain Injury), Brain Concussion, Clinical Trial, Rehabilitation, Cognition, Psychosocial Functioning, Walking, Vision, Ocular, Mobile Application, Saliva, microRNA, Exercise
Interventions: Brain & Walk Exercise Every Day (BraW-Day); Behavioral
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 18 Years to 40 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Interventions: Best Practice, Neuropsychological Assessment, Quality-of-Life Assessment, Questionnaire Administration; Other · Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: Brief Pain Inventory, Hospital Anxiety and Depression Scale, Neuropathic Pain Symptom Inventory, Diode Laser fiber type Selective Stimulator, Quantitative sensory testing, Conditioned pain modulation efficiency, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS); Other · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma, Leukemia, Myeloma, Lung Cancer
Interventions: MyoStrain®; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Suicide Risk
Interventions: TIPS Program, TIPS Program + ED-SAFE; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 32,406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Acute Cholecystitis, Chronic Cholecystitis
Interventions: TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia, TIVA - Tachycardia, INH - Hypotension, INH - Hypertension, INH - Bradycardia, INH - Tachycardia; Procedure
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: End Stage Liver Disease
Interventions: Advance Care Planning Video Decision Support Tool, Verbal Narrative; Behavioral · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-1-infection
Interventions: Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 40
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more

Search by objective public record fields.

Mitigating the Disinhibiting Effects of Alcohol With Transcranial Magnetic Stimulation

Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC)

Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema

Parents Helping Parents for Youth Vaping Cessation

Motivational Interviewing to Improve Oral Hygiene in Adolescent Orthodontic Patients

A Multi-Center Study of Reading Rehabilitation in Macular Disease

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

Iggy and the Inhalers: A Study to Assess the Impact of an Asthma Education Program in School Age Children

Evaluating a Blood Pressure Reduction and Weight Loss Program in a Low Income, Ethnically Diverse Population (The Be Fit, Be Well [BFBW] Study)

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

TAKE Steps: Motivational Interviewing to Prevent STIs

The VA-STRIDE Study

Lubiprostone in Children With Functional Constipation

Restoring Facial Volume After GLP-1 Weight Loss With Radiesse

Investigating the Role of the Polyol Pathway in the Central Nervous System

Acoustic Stimulation for Seizure Suppression

Dual-Task Exercise for Mild Traumatic Brain Injury (mTBI)

Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases

A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)

PROactive Evaluation of Function to Avoid CardioToxicity

Telehealth to Improve Prevention of Suicide (TIPS)

Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor

A Randomized Controlled Trial of an Advanced Care Planning Video Decision Support Tool for Patients With End-Stage Liver Disease

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)